Home / Immunome, Inc. (IMNM)
Stock Analysis
Immunome, Inc. (IMNM)
18.07 -1.69%
Updated: 2026-06-16 10:39 UTC
Technology-style analysis layer: price structure, momentum, key levels and business quality in one view.
WOI Investment Thesis
Vulnerable
Momentum: Neutral
Range: 52% of 52W range
Bull19.20
Base19.20
Bear
Key Levels
Resistance19.20
Support
Invalidation
Upside Target
Price Chart
IMNM · Interactive chart workspace
Open Full Workspace
Analyst Narrative
The latest close for Immunome, Inc. (IMNM) came in at 18.07 (-1.69%). Broader technical structure remains under pressure. Momentum remains weak (-13.46%); 52W position: 52% of range; and Volatility: ATR14 5.30%. RSI(14) sits near 33.3, which signals relatively weak momentum conditions. RSI has been drifting lower recently, suggesting that upside momentum may be cooling slightly. MACD is positioned under the signal line, suggesting momentum recovery has not fully developed yet. The MACD histogram remains negative, suggesting momentum is still on the softer side.
The chart is currently flagging Double top.
🎯
Key levels: On the upside, 19.20 is the nearest resistance area.
A cleaner push through that zone would improve continuation potential.
Technical Setup
🔺 Technical Setup
Breakout Watch
Downtrend line not broken yet · score 0
Watch Level
22.80
RSI(14)
33.3
Business Lens
💼 Fundamentals Snapshot
Source: sec
💼 Business Lens
QUALITY VIEW
Financial quality snapshot
Financial context is mixed
📈 Growth: Weak 💰 Profit: Insufficient 💵 Cash: Mixed 🛡 Balance: Manageable
• Quarterly revenue growth is slowing after a stronger phase.
• Quarterly profitability remains weak, with net margin below zero.
💵 Revenue
0.00
📈 Net Income
-53.84M
🧮 EPS (Basic)
-0.48
🏢 Company
Immunome, Inc.
🏷 Sector
Healthcare
🧩 Industry
Biotech
Compare with related stocks
Same sector and industry ideas for deeper research
Amgen (AMGN) technical analysisAxsome Therapeutics (AXSM) technical analysisBeam Therapeutics (BEAM) technical analysisCRISPR Therapeutics AG (CRSP) technical analysisAmicus Therapeutics (FOLD) technical analysisImmunitybio (IBRX) technical analysisAbbVie (ABBV) technical analysis
Note: This is an algorithmic technical snapshot, not financial advice.